HK1204261A1 - Immunogenic wt-1 peptides and methods of use thereof wt-1 - Google Patents

Immunogenic wt-1 peptides and methods of use thereof wt-1

Info

Publication number
HK1204261A1
HK1204261A1 HK15104710.4A HK15104710A HK1204261A1 HK 1204261 A1 HK1204261 A1 HK 1204261A1 HK 15104710 A HK15104710 A HK 15104710A HK 1204261 A1 HK1204261 A1 HK 1204261A1
Authority
HK
Hong Kong
Prior art keywords
immunogenic
peptides
methods
Prior art date
Application number
HK15104710.4A
Other languages
English (en)
Chinese (zh)
Inventor
Richard J Oreilly
Ekaterina Doubrovina
Annamalai Selvakumar
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of HK1204261A1 publication Critical patent/HK1204261A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15104710.4A 2012-01-13 2015-05-18 Immunogenic wt-1 peptides and methods of use thereof wt-1 HK1204261A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586177P 2012-01-13 2012-01-13
US201261647207P 2012-05-15 2012-05-15
PCT/US2013/021448 WO2013106834A2 (fr) 2012-01-13 2013-01-14 Peptides wt-1 immunogènes et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
HK1204261A1 true HK1204261A1 (en) 2015-11-13

Family

ID=48782099

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104710.4A HK1204261A1 (en) 2012-01-13 2015-05-18 Immunogenic wt-1 peptides and methods of use thereof wt-1

Country Status (8)

Country Link
US (3) US20150104413A1 (fr)
EP (2) EP3520810A3 (fr)
JP (2) JP6282598B2 (fr)
CN (2) CN104684577B (fr)
AU (2) AU2013207669C1 (fr)
CA (1) CA2861206C (fr)
HK (1) HK1204261A1 (fr)
WO (1) WO2013106834A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
KR102208505B1 (ko) 2012-12-11 2021-01-27 앨버트 아인슈타인 컬리지 오브 메디신 고처리량 수용체:리간드 확인을 위한 방법
WO2015164826A2 (fr) 2014-04-24 2015-10-29 Rhode Island Hospital Induction par l'aspartate-ss-hydroxylase d'une réponse des cellules t spécifique des épitopes dans les tumeurs
US10695385B2 (en) 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
CA2997757A1 (fr) * 2015-09-10 2017-03-16 Memorial Sloan Kettering Cancer Center Procedes de traitement du myelome multiple et de la leucemie a plasmocytes par therapie par cellules t
CN108604257B (zh) 2015-10-12 2022-12-13 南托米克斯有限责任公司 产生特异性免疫治疗组合物及其相关核酸构建体的方法
MA43283B1 (fr) 2015-11-20 2022-08-31 Memorial Sloan Kettering Cancer Center Composition pour le traitement du cancer
WO2017201210A1 (fr) 2016-05-18 2017-11-23 Cue Biopharma, Inc. Polypeptides multimères modulateurs des lymphocytes t et leurs procédé d'utilisation
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
JP7197481B2 (ja) 2016-11-30 2022-12-27 アドバクシス， インコーポレイテッド 反復性がん突然変異を標的とする免疫原性組成物およびその使用の方法
AU2017379900A1 (en) 2016-12-22 2019-06-13 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
SG10201914064QA (en) 2017-01-06 2020-03-30 Eutilex Co Ltd Anti-human 4-1 bb antibodies and use thereof
EP3565829A4 (fr) 2017-01-09 2021-01-27 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
EP3596118B1 (fr) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Procédés pour moduler une réponse immunitaire
CA3074839A1 (fr) 2017-09-07 2019-03-14 Cue Biopharma, Inc. Polypeptide multimere modulateur de lymphocyte t ayant des sites de conjugaison et procedes d'utilisation associes
EP3707152A4 (fr) * 2017-11-08 2021-12-01 Advaxis, Inc. Peptides hétéroclitiques immunogènes issus de protéines associées au cancer et procédés d'utilisation de ces peptides
WO2019139896A1 (fr) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
WO2019227106A1 (fr) * 2018-05-25 2019-11-28 The Wistar Institute Néo-antigènes spécifiques d'une tumeur et leurs méthodes d'utilisation
WO2020132366A2 (fr) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés
CN110423723A (zh) * 2019-07-18 2019-11-08 南方医科大学南方医院 一种外周血b细胞系的构建方法及其应用
CA3162690A1 (fr) 2019-12-31 2021-07-08 Minoru S. H. Ko Administration transitoire basee sur la temperature d'acides nucleiques et de proteines a des cellules et des tissus
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA8748A (fr) 1878-05-04 George W. Ainsworth Perfectionnements aux sechoirs a linge
CA23766A (fr) 1886-04-06 Albert M. Todd Procede de traitement des huiles volatiles pour en extraire le cristallin de la partie liquide
CA59350A (fr) 1898-02-26 1898-03-19 Thomas Henry Simmonds Frein pour velocipedes, tricycles, etc.
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
EP0573608A1 (fr) 1991-02-07 1993-12-15 Molecumetics, Ltd. Produits mimetiques de conformation restreinte de tours beta et bombements beta, et peptides les contenant
CA2158281A1 (fr) 1993-03-15 1994-09-29 Jay A. Berzofsky Cellules dentritiques revetues de peptide, agents immunogenes
AU2392795A (en) 1994-04-22 1995-11-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Isolation and characterization of a novel primate t-cell lymphotropic virus and the use of this virus or components thereof in diagnostics assays and vaccines
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6156316A (en) 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
JPH11171896A (ja) 1995-09-19 1999-06-29 Kirin Brewery Co Ltd 新規ペプチド化合物およびその医薬組成物
US5981217A (en) 1995-12-11 1999-11-09 Mayo Foundation For Medical Education And Research DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts
PT879282E (pt) 1996-01-17 2003-11-28 Imp College Innovations Ltd Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6207375B1 (en) 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
ID27813A (id) 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
BRPI9912663B8 (pt) 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20120301492A1 (en) 1998-09-30 2012-11-29 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
EP1144444A3 (fr) 1998-12-22 2002-01-02 Genset Adn complementaires codant pour des proteines secretees avec des peptides signaux
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2367692A1 (fr) 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Cellules dendritiques transduites avec un gene du soi de type sauvage suscitant des reponses immunitaires antitumorales puissantes
US6593299B1 (en) * 1999-04-21 2003-07-15 University Of Florida Research Foundation, Inc. Compositions and methods for controlling pests
AU7859900A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
AU2001247220A1 (en) * 2000-02-22 2001-09-03 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP1209226A3 (fr) 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation de cellules dendritiques grâce à la protéine de choc thermique 70 (hsp70) recombinante
TWI318630B (en) 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
DE60238958D1 (de) 2001-06-29 2011-02-24 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
EP1447091A4 (fr) 2001-09-28 2008-02-13 Institute Of Can International Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
CN101113163B (zh) 2002-06-12 2010-10-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
KR101173871B1 (ko) 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
US20050008618A1 (en) 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
WO2004111075A2 (fr) * 2003-03-05 2004-12-23 Dendreon Corporation Compositions et procedes utilisant des polypeptides a cadre de lecture differents dans le traitement du cancer et de maladies infectieuses
KR101431312B1 (ko) 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
ES2378264T3 (es) 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. Péptido antigénico de unión a HLA-DR derivado de WT1
US7488718B2 (en) 2003-12-01 2009-02-10 Sloan Kettering Institue For Cancer Research Synthetic HLA binding peptide analogues and uses thereof
ATE426617T1 (de) 2003-12-05 2009-04-15 Multimmune Gmbh Therapeutische und diagnostische anti-hsp 70- antikírper
EP1550458A1 (fr) 2003-12-23 2005-07-06 Vectron Therapeutics AG Adjuvants liposomals synergiques
EP1720565A1 (fr) 2004-03-04 2006-11-15 Corixa Corporation Formulations d'immunostimulants en microspheres et de polypeptide wt1 en co-encapsulation, et procedes correspondants
US20050214268A1 (en) 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20050221481A1 (en) 2004-03-30 2005-10-06 Istituto Superiore Di Sanita' Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2
ATE462003T1 (de) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
US9629927B2 (en) 2005-07-29 2017-04-25 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses thereof
EP1951281B1 (fr) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides
KR101385805B1 (ko) * 2005-11-30 2014-04-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 신규 펩티드 화합물
PL1988163T3 (pl) 2006-02-22 2012-11-30 Int Inst Cancer Immunology Inc Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna
WO2007119564A1 (fr) 2006-03-29 2007-10-25 International Institute Of Cancer Immunology, Inc. ARNsi SPÉCIFIQUE DE L'ISOFORME WT1 17AA(-) ET SON UTILISATION
EP3117836A1 (fr) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Peptides wt-1 immunogènes et leurs utilisations
WO2007120603A2 (fr) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Peptides bcr-abl immunogènes et leurs méthodes d'utilisation
CN101663323A (zh) 2006-12-27 2010-03-03 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
DK2341142T3 (en) 2006-12-28 2014-12-08 Int Inst Cancer Immunology Inc HLA-A * 1101-restricted WT1 peptide or pharmaceutical composition comprising this
WO2008096831A1 (fr) 2007-02-07 2008-08-14 The Research Foundation For Microbial Diseases Of Osaka University Agent thérapeutique contre le cancer
CN103103246B (zh) 2007-02-27 2018-05-01 株式会社癌免疫研究所 活化辅助t细胞的方法以及用于该方法的组合物
KR20110091817A (ko) 2007-05-24 2011-08-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
KR100995340B1 (ko) 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신
KR101592855B1 (ko) 2007-12-05 2016-02-12 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 백신 조성물
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
CA2724649A1 (fr) 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comportant un mutant prfa de listeria, et leurs procedes d'utilisation
EP2337795A2 (fr) * 2008-10-01 2011-06-29 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
WO2011059835A2 (fr) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Mutations wt1 pour le pronostic de troubles myéloprolifératifs
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
MX353165B (es) 2010-08-24 2017-12-20 Univ Of Pittsburgh Of The Commonwealth System Of Higher Education Star Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
WO2012046730A1 (fr) 2010-10-05 2012-04-12 国立大学法人大阪大学 Procédé d'activation d'une cellule t auxiliaire
AP2013007158A0 (en) 2011-03-11 2013-10-31 Gilead Calistoga Llc Combination therapies for hematologic malignancies
CA2839663A1 (fr) 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Gene recepteur pour un lymphocyte t specifique d'un antigene cancereux peptidique
EP2738253A4 (fr) 2011-07-29 2015-04-22 Riken Cellule utilisable en immunothérapie qui contient un produit de recombinaison de type acide nucléique modifié codant pour un produit du gène de la tumeur de wilms ou pour un fragment de celui-ci, procédé de production de ladite cellule et dudit produit de recombinaison de type acide nucléique
US9539299B2 (en) 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
CN104136609B (zh) 2011-12-14 2016-12-07 国立大学法人高知大学 辅助性t细胞诱导多肽的修饰
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9751928B2 (en) 2012-05-03 2017-09-05 Fred Hutchinson Cancer Research Center Enhanced affinity T cell receptors and methods for making the same
JP6163486B2 (ja) 2012-07-02 2017-07-12 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
EP2911683B1 (fr) 2012-10-23 2019-09-25 Ubivac, LLC Composition enrichie en autophagosome allogénique pour le traitement de maladies
EP2933261B1 (fr) 2012-12-17 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Procédé pour activer des lymphocytes t auxiliaires
WO2014103310A1 (fr) 2012-12-26 2014-07-03 バイオコモ株式会社 Vaccin préparé à l'aide d'un vecteur du virus parainfluenza humain de type 2
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
CA2840988A1 (fr) 2013-02-05 2014-08-05 Nitto Denko Corporation Composition de vaccin contre le cancer avec peptide wt1 pour administration muqueuse
RU2685933C2 (ru) 2013-02-05 2019-04-23 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
JP6512569B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤
EP2956544B1 (fr) 2013-02-14 2017-11-01 Immunocellular Therapeutics Ltd. Vaccins contre le cancer et méthodes de vaccination
ES2694328T3 (es) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
US11419925B2 (en) 2013-03-15 2022-08-23 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
MX364459B (es) 2013-03-29 2019-04-26 Sumitomo Dainippon Pharma Co Ltd Vacuna de conjugado de péptido-antígeno de wt1.
MX364922B (es) 2013-04-25 2019-05-14 Vaximm Ag Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer.
KR20160007579A (ko) 2013-05-13 2016-01-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 면역요법의 임상 효과의 예측법
US10898555B2 (en) 2013-07-02 2021-01-26 Japanese Foundation For Cancer Research Cellular immunity inducing vaccine
PL3071593T3 (pl) 2013-11-22 2019-11-29 Univ Illinois Konstruowane ludzkie receptory komórek T o wysokim powinowactwie
RU2016129044A (ru) 2013-12-18 2018-01-23 Факсимм Гмбх Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака
CA2935375C (fr) 2014-01-06 2023-08-08 The Trustees Of The University Of Pennsylvania Anticorps pd1 et pdl1 et combinaisons de vaccin et utilisation de celles-ci pour l'immunotherapie
EP3104878B1 (fr) 2014-02-14 2019-05-22 Immune Design Corp. Immunothérapie du cancer par combinaison de stimulation immunitaire locale et systémique
WO2015129790A1 (fr) 2014-02-26 2015-09-03 株式会社バイオイミュランス Polypeptide antigénique wt1, et agent antitumoral contenant ledit polypeptide
US10023841B2 (en) 2014-05-23 2018-07-17 Baylor Research Institute Methods and compositions for treating breast cancer with dendritic cell vaccines
US10525096B2 (en) 2014-12-11 2020-01-07 International Institute Of Cancer Immunology, Inc. Immunotherapy for angiogenic disease
US10695385B2 (en) 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
US20190054112A1 (en) 2015-09-18 2019-02-21 Moderna Therapeutics, Inc. Polynucleotide formulations for use in the treatment of renal diseases

Also Published As

Publication number Publication date
EP2802347A2 (fr) 2014-11-19
AU2018201210A1 (en) 2018-03-08
JP2015512866A (ja) 2015-04-30
WO2013106834A3 (fr) 2015-01-22
US10815274B2 (en) 2020-10-27
CN104684577A (zh) 2015-06-03
EP2802347A4 (fr) 2016-06-01
WO2013106834A2 (fr) 2013-07-18
AU2018201210B2 (en) 2020-04-09
AU2013207669A1 (en) 2014-08-07
EP2802347B1 (fr) 2019-01-09
CA2861206A1 (fr) 2013-07-18
US20190092813A1 (en) 2019-03-28
JP6995645B2 (ja) 2022-01-14
EP3520810A2 (fr) 2019-08-07
US10100087B2 (en) 2018-10-16
EP3520810A3 (fr) 2019-11-06
CN104684577B (zh) 2018-05-08
JP2018104438A (ja) 2018-07-05
CN108676069A (zh) 2018-10-19
CA2861206C (fr) 2021-07-06
AU2013207669B2 (en) 2017-11-23
AU2013207669C1 (en) 2018-05-31
US20170334951A1 (en) 2017-11-23
JP6282598B2 (ja) 2018-02-21
AU2013207669B9 (en) 2017-12-14
US20150104413A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
HK1204261A1 (en) Immunogenic wt-1 peptides and methods of use thereof wt-1
PT2945647T (pt) Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
EP2912178A4 (fr) Super-activateurs et procédés d'utilisation de ceux-ci
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
HK1199892A1 (en) Modified mini-hepcidin peptides and methods of using thereof
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
PT2925782T (pt) Anticorpos anti-cd47 e métodos de utilização destes
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
EP2895083A4 (fr) Ligateur et procédé d'utilisation
EP2870170A4 (fr) Nouveaux peptides et leur utilisation
HK1206037A1 (en) Human antibodies to gfr3 and methods of use thereof gfr3
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
HK1197187A1 (en) Anti-lrp5 antibodies and methods of use lrp5
EP2782589A4 (fr) Peptides antimicrobiens et procédés d'utilisation de ces derniers
HK1225645A1 (zh) Pcv2b趨異株疫苗組合物以及使用方法
EP2863858A4 (fr) Systèmes de soutien pour patient et leurs procédés d'utilisation
EP2806811A4 (fr) Construction vertébrale
HK1203161A1 (en) Peptides and methods of using same
EP2938632A4 (fr) Anticorps anti-granulysine et leurs procédés d'utilisation
EP2897639A4 (fr) Compositions de vaccins perfectionnées et méthodes d'utilisation
EP2852397A4 (fr) Variants d'huwentoxine iv et procédés d'utilisation
HK1209432A1 (en) Anti-jagged antibodies and methods of use
SG11201504805PA (en) Porcine parvovirus 5a, methods of use and vaccine
EP2897680A4 (fr) Dispositifs de gonflage et leurs procédés d'utilisation
EP2925341A4 (fr) Composés peptidiques et leurs procédés de production et d'utilisation